Comunicati stampa

San Ramon, CA, USA – Oct. 07, 2019 – BioVentrix, Inc. announced the first patient was enrolled and treated in the REVIVE-HF European study, a prospective multi-center, dual-arm randomized controlled study evaluating the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC System compared to Guideline-Directed Medical Therapy (GDMT) or drug treatment. 


 

San Ramon, Calif., February 28, 2019 — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced a significant reimbursement achievement. InEk, the German Institute for Hospital Remuneration, has reconfirmed the award of NUB Status 1 for the Revivent TC™ TransCatheter Ventricular Enhancement System.


Image

BioVentrix è una società privata di dispositivi medici con sede a San Ramon, in California, negli Stati Uniti.

Le nostre notizie

Contattaci

© 2019 BioVentrix. Tutti i diritti riservati. Realizzato da MedTech Momentum
Il marchio Revivent TC ™ è un marchio registrato a livello federale di proprietà di BioVentrix. Qualsiasi utilizzo non autorizzato è espressamente vietato.